

Increased Sympathetic and Decreased Parasympathetic Activity Rather Than Changes in Hypothalamic-Pituitary-Adrenal Axis Activity Is Associated with Metabolic Abnormalities

Carmilla M. M. Licht,* Sophie A. Vreeburg,* Arianne K. B. van Reedt Dortland, Erik J. Giltay, Witte J. G. Hoogendijk, Roel H. DeRijk, Nicole Vogelzangs, Frans G. Zitman, Eco J. C. de Geus, and Brenda W. J. H. Penninx

Department of Psychiatry and EMGO Institute for Health and Care Research (C.M.M.L., S.A.V., W.J.G.H., N.V., B.W.J.H.P.) and Neuroscience Campus Amsterdam (W.J.G.H., E.J.C.d.G.), Vrije Universiteit Medical Center, and Department of Biological Psychology (E.J.C.d.G.), Vrije Universiteit, 1081 HL Amsterdam, The Netherlands; Department of Psychiatry (A.K.B.v.R., E.J.G., R.H.D., F.G.Z., B.W.J.H.P.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands; and Department of Psychiatry (B.W.J.H.P.), University Medical Center Groningen, 9700 RB Groningen, The Netherlands

Context: Stress is suggested to lead to metabolic dysregulations as clustered in the metabolic syndrome, but the underlying biological mechanisms are not yet well understood.

Objective: We examined the relationship between two main str systems, the autonomic nervous system and the hypothalamic-pituitary-adrenal (HPA) axis, with the metabolic syndrome and its components.

Design: The design was baseline data (yr 2004–2007) of a prospective cohort: the Netherlands Study of Depression and Anxiety (NESDA).

Setting: The study comprised general community, primary care, and specialized mental health care.

Participants: This study included 1883 participants aged 18–65 yr.

Main Outcome Measures: Autonomic nervous system measures included heart rate, respiratory sinus arrhythmia (RSA; high RSA reflecting high parasympathetic activity), and preejection period (PEP; high PEP reflecting low sympathetic activity). HPA axis measures included the cortisol awakening response, evening cortisol, and a 0.5 mg dexamethasone suppression test as measured in saliva. Metabolic syndrome was based on the updated Adult Treatment Panel III criteria and included high waist circumference, serum triglycerides, blood pressure, serum glucose, and low high-density lipoprotein cholesterol.

Results: RSA and PEP were both independently negatively associated with the presence of the metabolic syndrome, the number of metabolic dysregulations as well as all individual components except high-density lipoprotein cholesterol (all $P < 0.02$). Heart rate was positively related to the metabolic syndrome, the number of metabolic dysregulations, and all individual components (all $P < 0.001$). HPA axis measures were not related to metabolic syndrome or its components.

Conclusion: Our findings suggest that increased sympathetic and decreased parasympathetic nervous system activity is associated with metabolic syndrome, whereas HPA axis activity is not. (*J Clin Endocrinol Metab* 95: 2458–2466, 2010)

It has often been hypothesized that stress leads to metabolic dysregulations (1–3). In response to stress, two main stress systems, the autonomic nervous system (ANS) and the hypothalamic-pituitary-adrenal (HPA) axis, are both centrally activated (2, 3). Persistent (over)activation of these stress systems could lead to metabolic alterations, such as high blood pressure, serum triglycerides, serum glucose, waist circumference, and low high-density lipoprotein (HDL) cholesterol (3–5). The metabolic syndrome consists of a cluster of these metabolic abnormalities and predisposes to cardiovascular disease (6, 7) and diabetes (8). Whether both stress systems are associated with the metabolic syndrome has only partially been examined (4, 5, 10).

Some studies have shown evidence for a role of ANS dysfunction in the metabolic syndrome. For sympathetic nervous system (SNS) activity, measured by, for example, muscle sympathetic nerve activity, elevated levels were found in subjects with metabolic syndrome (11, 12). However, Grassi *et al.* (12) showed that different measures of SNS activity show divergent associations with the metabolic syndrome; therefore, evidence for the relationship between purely sympathetic activity and the metabolic syndrome remains ambiguous and cannot be considered conclusive. More evidence is present for a negative relationship between parasympathetic nervous system (PNS) activity and the metabolic syndrome (13–15), although inconsistencies have been found. For example, PNS activity (as reflected by the high frequency spectra of heart rate variability) was unassociated (14, 16) as well as negatively associated with having the metabolic syndrome (13, 15). Studies have also shown inconsistent results for the association of PNS activity with various metabolic dysregulations (13–15). In addition, some studies were limited by rather short periods of physiological recordings or no consideration of cardiovascular disease and cardiac medication (13–15).

Cortisol measured in saliva is considered a reliable and noninvasive indicator of HPA axis activity (17). Although there are several studies that examined the association between salivary cortisol and the metabolic syndrome or its components, the relationship is still not elucidated. Results are inconsistent concerning the direction of the relationship as well as the aspect of the cortisol diurnal rhythm that might be involved. For instance, no (18, 19), negative (20, 21), and positive (22, 23) associations have been reported between salivary morning cortisol or cortisol awakening response and components of the metabolic syndrome. Studies specifically examining evening cortisol and metabolic syndrome components are scarce, mostly reporting no association (18, 21). Results regarding cortisol suppression after dexamethasone ingestion showed

less suppression after dexamethasone to be associated with hypertension (21) and all other metabolic syndrome components (20), whereas Putignano *et al.* (19) reported no association with obesity. However, previous studies were rather small, measured morning cortisol by only one salivary sample, or did not adjust for important covariates such as sleep duration and awakening time.

Therefore, we examined the association between metabolic syndrome and its components with multiple extensive measures of both ANS and HPA axis activity in a large cohort study considering important covariates to explore to what extent both stress systems are involved in metabolic abnormalities.

Subjects and Methods

Study sample

Data are from The Netherlands Study of Depression and Anxiety (NESDA), a large longitudinal cohort study among 2981 adults (18–65 yr), 95.2% of North European ancestry (see Ref. (24)). Respondents were recruited from the community, in primary care through a screening procedure conducted among 65 general practitioners, and in specialized mental health care when newly enrolled at one of the 17 participating mental health organization locations.

The research protocol was approved by the ethical committee of participating universities and all respondents provided written informed consent.

Of the total sample, we excluded 80 persons using tricyclic antidepressants because of their effect on the ANS (25), HPA axis (26), and metabolic syndrome (27). Of the 2901 remaining participants, we excluded 27 pregnant or breast-feeding women and 158 participants on corticosteroids because of their effects on the HPA axis, leaving a sample of 2716 respondents. Of 109 participants, no ANS data were available, another 695 did not return (sufficient) saliva samples for HPA axis activity assessment, and of 29 persons data on metabolic abnormalities were missing. Therefore, the present study sample consisted of 1883 participants.

Participants in the present study sample ($n = 1883$) did not differ from the excluded participants ($n = 833$) in presence of metabolic syndrome (21.1 *vs.* 23.4%, $P = 0.17$) or cardiovascular disease (5.8 *vs.* 7.1%, $P = 0.18$) but were less often female (64.9 *vs.* 68.9%, $P = 0.02$), older (43.0 *vs.* 39.9 yr, $P < 0.001$), and more educated (12.4 *vs.* 11.7 yr, $P < 0.001$).

Outcome measures

Metabolic syndrome

The metabolic syndrome was defined according to the American Heart Association and National Heart, Lung, and Blood Institute's update of the U.S. National Cholesterol Education Program-Adult Treatment Panel III criteria (28). The National Cholesterol Education Program-Adult Treatment Panel III guidelines define metabolic syndrome as a presence of three or more of the following criteria: 1) waist circumference 102 cm or greater in men and 88 cm or greater in women, 2) triglycerides 1.7 mmol/liter or greater (150 mg/dl) or medication for hyper-

triglyceridemia, 3) HDL cholesterol less than 1.03 mmol/liter (40 mg/dl) in men and less than 1.30 mmol/liter (50 mg/dl) in women or medication for reduced HDL cholesterol, 4) systolic blood pressure (SBP) 130 mm Hg or greater and/or diastolic blood pressure 85 mm Hg or greater or antihypertensive medication, and 5) fasting plasma glucose 5.6 mmol/liter or greater (100 mg/dl) or antidiabetic medication. The number of metabolic syndrome components was used as an indicator of severity of metabolic abnormalities (27).

Metabolic syndrome components

In addition to metabolic syndrome, associations with continuous levels of individual metabolic components were examined to investigate consistency across components. Waist circumference was measured with a measuring tape at the central point between the lowest front rib and the highest front point of the pelvis on light clothing. Triglycerides, HDL cholesterol, and glucose were determined using routine standardized laboratorial methods. To incorporate medication use into the continuous variable, for persons using antidiabetic medication when glucose level was less than 7.0 mmol/liter (126 mg/dl), a value of 7.0 mmol/liter (126 mg/dl) was assigned (28). Similarly, for persons using fibrates, 0.10 mmol/liter (3.8 mg/dl) was subtracted from HDL cholesterol and 0.67 mmol/liter (60 mg/dl) was added to triglycerides (28). For persons using nicotinic acid, 0.15 mmol/liter (5.8 mg/dl) was subtracted from HDL cholesterol and 0.19 mmol/liter (17 mg/dl) added to triglycerides, based on mean changes after medication treatment (28). SBP and diastolic blood pressure were measured twice during supine rest on the right arm with the Omron M4-I, HEM 752A, and were averaged over the two measurements. For persons using antihypertensive medication, 10 mm Hg was added to the SBP (29).

Measurements

ANS

During the visit to the research centers, The Netherlands Study of Depression and Anxiety subjects were wearing the Vrije Universiteit ambulatory monitoring system. The Vrije Universiteit ambulatory monitoring system is a light-weight, unobtrusive device that records the electrocardiogram (ECG) and changes in thorax impedance (dZ) from six surface electrodes placed at the chest and on the back of the subjects (30, 31). The interbeat interval time series was extracted from the ECG signal to obtain heart rate, an indicator of combined SNS and PNS activity. To separately index the cardiac effects of both ANS branches, preejection period (PEP; high PEP reflects low SNS activity) and respiratory sinus arrhythmia (RSA; high RSA reflects high PNS activity) were extracted from the combined dZ and ECG signals.

The PEP reflects noradrenergic inotropic drive to the left ventricle and was obtained from the dZ/dt signal, ensemble averaged across 1-min periods time locked to the R-wave of the ECG. The PEP was defined as the interval from the B point (upstroke) to the X point (incisura) of the dZ/dt signal, as described in detail elsewhere (31). The RSA reflects cardiac parasympathetic activity and was obtained by combining the interbeat interval time series with the filtered (0.1–0.4 Hz) dZ signal, which corresponds to the respiration signal. RSA was obtained by subtracting the shortest interbeat interval (IBI) during heart rate acceleration in the inspirational phase from the longest IBI during deceleration

in the expirational phase for all breaths, as described in detail elsewhere (30). Automated scoring of IBI, RSA, and PEP was checked by visual inspection, and valid data were averaged over 90.2 ± 23 min time to create a single PEP, RSA, and heart rate value.

To additionally investigate whether patterns of sympathetic and parasympathetic coactivation or parallel activation/inhibition were related to the metabolic syndrome, two measures of autonomic balance were acquired following the approach of Berntson *et al.* (32). Cardiac autonomic balance (CAB) was calculated as the difference between normalized values of RSA and PEP [formula = $zRSA - (-zPEP)$ (because increased sympathetic control is associated with shortened PEP values, PEP was multiplied by -1)] such that low values reflect parallel high sympathetic and low vagal cardiac control (unfavorable cardiac pattern) and high values reflect low sympathetic and high vagal cardiac control (favorable cardiac pattern). Cardiac autonomic regulation (CoAR) was calculated as the sum of the normalized values of RSA and PEP [formula = $zRSA + (-zPEP)$] and low values represent coinhibition (low SNS and low PNS activity) and high values coactivation (high SNS and high PNS activity) of the two cardiac branches.

HPA axis

As described in more detail elsewhere (33), respondents were instructed to collect saliva samples at home on a regular (working) day, which has shown a reliable and minimally intrusive method to assess the active, unbound form of cortisol (17). The median time between the interview and saliva sampling was 9.0 d (25th to 75th percentile: 4–22). Saliva samples were obtained using Salivettes (Sarstedt, Germany) at seven time points. The cortisol awakening response includes four sampling points; at awakening (T1) and 30 (T2), 45 (T3), and 60 (T4) min later. Two evening values were collected at 2200 h (T5) and 2300 h (T6). Dexamethasone suppression was measured by cortisol sampling the next morning at awakening (T7) after ingestion of 0.5 mg dexamethasone directly after the saliva sample at 2300 h (T6). Samples were stored in refrigerators and returned by mail. After receipt, Salivettes were centrifuged at 2000 g for 10 min, aliquoted, and stored at -80 C. Cortisol analysis was performed by competitive electrochemiluminescence immunoassay (E170; Roche, Basel, Switzerland), as described in Van Aken *et al.* (34). The functional detection limit was 2.0 nmol/liter and the intra- and interassay variability coefficients in the measuring range were less than 10%. Data cleaning excluded values greater than 2 SD above the mean (*i.e.* above 59.6–123.6 nmol/liter for T1–T4, 40.9 nmol/liter for T5, 59.8 nmol/liter for T6, and 35.6 nmol/liter for T7).

One-hour awakening cortisol

The area under the curve with respect to the increase (AUC_i) and ground (AUC_g) were calculated using the formulas described by Pruessner *et al.* (35). The AUC_g is an estimate of the total cortisol secretion over the first hour after awakening, and the AUC_i is a measure of the dynamic of the cortisol awakening response, more related to the sensitivity of the system, emphasizing changes over time (36). For area under the curve calculations, all four morning samples were required ($n = 1584$).

Evening cortisol

Because the correlation between the two evening values was high ($r = 0.52$, $P < 0.001$), the mean of the two values was used for analyses to reflect evening cortisol ($n = 1871$).

Dexamethasone suppression test

A total of 1712 of the 1781 subjects with cortisol sample T1 and T7 (96.1%) had taken the 0.5 mg dexamethasone after 2300 h on the first sampling day. We used a cortisol suppression ratio calculated by cortisol value at awakening on the first day (T1) divided by cortisol value at awakening the next day (T7) after ingestion of 0.5 mg dexamethasone the evening before.

Covariates

Sociodemographic factors included sex, age, and years of attained education. Use of oral contraceptives (yes/no) and menopause (yes/no) were identified by self-report. Smoking status was categorized into never smoked, former smoker, and current smoker. Daily alcohol use was categorized into no, mild to moderate (maximal 2 U/d), and heavy (>2 U/d). Physical activity was assessed by the International Physical Activity Questionnaire (37) and expressed in 1000 metabolic equivalent minutes in the past week. Cardiovascular disease (including coronary disease, cardiac arrhythmia, angina, heart failure, and myocardial infarction) was ascertained by self-report. Furthermore, it was determined whether subjects were using heart medication by copy-

TABLE 1. Sample characteristics

	Metabolic syndrome		<i>P</i> ^a
	No (<i>n</i> = 1484)	Yes (<i>n</i> = 399)	
Sociodemographics			
Age (yr) (mean ± sd)	41.1 ± 13.0	50.4 ± 10.1	<0.001
Female (%)	68.5	51.6	<0.001
Education (yr) (mean ± sd)	12.7 ± 3.2	11.3 ± 3.3	<0.001
Health factors			
Physical activity (1000 MET min/wk) (mean ± sd)	3.7 ± 3.0	3.6 ± 3.0	0.36
Smoking (%)			
Nonsmoker	32.0	22.6	<0.001
Former smoker	35.2	45.1	
Current smoker	32.8	32.3	
Alcohol use (%)			
Nondrinker	14.4	19.5	0.003
Mild/moderate drinker	69.9	61.2	
Heavy drinker	15.7	19.3	
Use β-blockers (%)	4.3	22.1	<0.001
Use other heart medication (%)	5.7	30.3	<0.001
Use of oral contraceptives (%)	19.5	6.8	<0.001
Postmenopausal women (%)	18.7	26.6	0.001
Cardiovascular disease (%)	5.7	11.5	<0.001
Time of awakening (mean ± sd)	7 h 31 min ± 1 h 16 min	7 h 19 min ± 1 h 06 min	0.006
Working on day of sampling (%) (% yes)	63.4	56.4	0.01
Sampling in month with more daylight (%)	58.6	57.9	0.79
6 h or less of sleep (%)	24.7	32.3	0.002
Autonomic measures			
RSA (msec) (mean ± sd)	46.1 ± 24.5	32.2 ± 19.8	<0.001
HR (beats/min) (mean ± sd)	71.1 ± 9.3	72.0 ± 10.5	0.06
PEP (msec) (mean ± sd)	122.9 ± 16.2	119.8 ± 21.9	0.005
CAB (mean ± sd)	0.158 (1.33)	−0.593 (1.57)	<0.001
CoAR (mean ± sd)	0.053 (1.33)	−0.323 (1.42)	<0.001
HPA axis measures			
AUCg (nmol/liter · h) (mean ± sd)	19.0 ± 7.1	19.6 ± 6.9	0.18
AUCi (nmol/liter · h) (mean ± sd)	2.4 ± 6.2	2.1 ± 6.6	0.48
Mean evening level (nmol/liter) (mean ± sd)	5.4 ± 3.5	5.6 ± 3.0	0.31
Cortisol suppression ratio (mean ± sd) ^b	2.9 ± 1.7	2.7 ± 1.6	0.10
Continuous measures of MetSYn			
Waist circumference (cm) (mean ± sd)	85.0 ± 11.2	103.3 ± 11.8	<0.001
SBP (mm Hg) (mean ± sd)	133.0 ± 17.8	151.8 ± 19.4	<0.001
Glucose (mmol/liter) (mean ± sd)	4.9 ± 1.1	5.9 ± 1.2	<0.001
HDL cholesterol (mmol/liter) (mean ± sd)	1.7 ± 0.4	1.3 ± 0.4	<0.001
Triglycerides (mmol/liter) (mean ± sd)	1.0 ± 1.5	1.8 ± 1.6	<0.001
Number of metabolic components (mean ± sd)	1.0 ± 0.8	3.5 ± 0.7	<0.001

MET, Metabolic energy turnover; HR, heart rate.

^a Based on χ^2 and ANOVA statistics for dichotomous or categorical and continuous measures, respectively.

^b Cortisol suppression ratio = cortisol T1/cortisol T7 after 0.5 mg dexamethasone glucose and triglyceride levels are backtransformed.

TABLE 2. Correlation coefficients of partial correlation between HPA axis and ANS measures^a

	AUCg (nmol/liter · h)	AUCi (nmol/liter · h)	Evening cortisol (nmol/liter · h)	Suppression ratio
RSA (msec)	−0.031	−0.027	−0.016	−0.010
HR (beats/min)	0.040	0.038	0.020	0.039
PEP (msec)	0.037	0.006	0.046	−0.038
CAB	0.020	−0.002	0.043	−0.037
CoAR	−0.039	−0.013	−0.030	0.041

HR, Heart rate.

^a Adjusted for age, sex, and education.

ing the names of medicines from the containers brought in by the subjects. Using the World Health Organization's anatomical therapeutic chemical (ATC) classification, medication was classified. Use both of β -blockers (ATC code C07, used daily or more than 50% of the time) and other heart medication [ATC codes C01 (cardiac therapy), C02 (antihypertensives), C03 (diuretics), C04 (peripheral vasodilators), C05 (vasoprotectives), C08 (calcium channel blockers), or C09 (renin and angiotensin agents)] was ascertained. Additionally, for analyses with cortisol measures, sampling factors that have been shown to influence cortisol measures by Vreeburg *et al.* (33) were included. Respondents reported time of awakening and working status on the sampling day. Season was categorized into dark months (October through February) and months with more daylight (March through September). Average sleep duration during the last week was assessed using the Insomnia Rating Scale (38) and dichotomized into sleeping more or less than 6 h a night.

Statistical analyses

Baseline characteristics were compared across metabolic syndrome status using χ^2 and ANOVA statistics. Partial correlation coefficients (adjusting for age, sex, and education) between ANS and cortisol measures were calculated to examine the intercorrelations between both stress systems. Multiple logistic regression analyses were conducted with ANS measures (*i.e.* heart rate, RSA, or

PEP) and salivary cortisol measures (*i.e.* AUCg, AUCi, evening cortisol, or cortisol suppression ratio) as independent variables and metabolic syndrome as the dependent variable. Multiple linear regression, adjusted for all covariates, was used to analyze the association of ANS and salivary cortisol measures with either the number of metabolic syndrome components (0–5) or continuous individual metabolic syndrome components as dependent variables. All metabolic syndrome components were normally distributed, except for triglycerides and glucose levels, which were log transformed before analyses. If linear regression with the number of metabolic syndrome components yielded significant results; fully corrected analysis of covariance analyses were performed to compare the mean ANS and HPA axis values of persons with increasing number of metabolic syndrome components (*i.e.* 0, 1, 2, 3, 4, and 5) and investigate linearity. $P \leq 0.05$ was regarded as statistically significant. All analyses were conducted using SPSS version 15.0 (SPSS, Chicago, IL).

Results

In our sample, 21.2% met the criteria for the metabolic syndrome; 25.1% met none of the criteria, 31.3% one, 22.4% two, 12.9% three, 6.4% four, and 1.9% all five

TABLE 3. Adjusted associations between the stress systems (per 10 U increase) and metabolic syndrome and number of metabolic syndrome components^a

	Metabolic syndrome		Number of metabolic syndrome components	
	OR (95% CI)	P	β	P
ANS				
RSA (per 10 ms increase)	0.81 (0.74–0.90)	<0.001	−0.110	<0.001
HR (per 10 beats/min increase)	1.72 (1.46–2.02)	<0.001	0.220	<0.001
PEP (per 10 msec increase)	0.87 (0.80–0.94)	<0.001	−0.132	<0.001
CAB (per 1 U increase)	0.75 (0.67–0.84)	<0.001	−0.163	<0.001
CoAR (per 1 U increase)	1.06 (0.94–1.20)	0.31	0.045	0.12
HPA axis				
AUCg (per 10 nmol/liter · h increase)	1.07 (0.88–1.29)	0.50	0.008	0.72
AUCi (per 10 nmol/liter · h increase)	1.05 (0.85–1.30)	0.65	−0.003	0.87
Evening cortisol (per 10 nmol/liter increase)	0.84 (0.57–1.23)	0.36	−0.012	0.56
Cortisol suppression ratio (per 1 U increase)	1.05 (0.87–1.26)	0.64	0.004	0.87

OR, Odds ratio; CI, confidence interval; β , standardized β -coefficient; HR, heart rate.

^a Based on logistic and linear regression analyses adjusted for age, sex, education, oral contraceptive use, menopause, cardiovascular disease, physical activity, smoking, alcohol use, and use of β -blockers and other heart medication. For HPA axis, analyses are additionally adjusted for working, awakening time, season, and sleep.

criteria. Sample characteristics are presented in Table 1. Persons with the metabolic syndrome were more likely to be male, older, and less educated, a nondrinker or heavy drinker, a former smoker, using heart medication, or having prevalent cardiovascular disease and were less likely to be using oral contraceptives than persons without the metabolic syndrome. Persons with the metabolic syndrome showed on average a lower RSA, CAB, and CoAR, higher heart rate, and shorter PEP, whereas no differences were seen in cortisol measures, except for a trend toward less suppression after dexamethasone.

Table 2 shows the results of the partial correlations between HPA axis measures and ANS measures adjusted for age, sex, and education. In contrast to an expected intercorrelatedness because of shared central activation of both stress systems, ANS measures did not significantly correlate with HPA axis measures (all $P > 0.11$).

After full adjustment, RSA, heart rate, and PEP were significantly related to the metabolic syndrome as well as the number of metabolic abnormalities (Table 3 and Fig. 1). The odds for the metabolic syndrome increased when RSA and PEP decreased, indicating that decreased parasympathetic and increased sympathetic activity are associated with increased likelihood of metabolic syndrome. Lower RSA and PEP were also associated with the number of metabolic syndrome components present (Table 3 and Fig. 1). A higher heart rate was associated with an increased odds for metabolic syndrome and an increase in number of metabolic syndrome components. None of the HPA axis measures was associated with the metabolic syndrome or with the number of its components (Table 3).

Table 4 shows the associations of ANS and HPA axis measures with the different continuous metabolic syndrome components. Again, salivary cortisol measures were not significantly related to the continuous metabolic syndrome components. However, RSA (increased PNS activity) and PEP (decreased sympathetic activity) were negatively associated with waist circumference ($\beta = -0.078$, $P = 0.005$ and $\beta = -0.143$, $P < 0.001$, respectively), triglycerides ($\beta = -0.092$, $P = 0.002$ and $\beta = -0.081$, $P = 0.001$, respectively), and SBP ($\beta = -0.111$, $P < 0.001$ and $\beta = -0.115$, $P < 0.001$, respectively). RSA was also negatively associated with glucose ($\beta = -0.066$, $P = 0.02$). Heart rate was positively associated with waist circumference ($\beta = 0.111$, $P < 0.001$), triglycerides ($\beta = 0.186$, $P < 0.001$), SBP ($\beta = 0.150$, $P < 0.001$), and glucose ($\beta = 0.140$, $P < 0.001$) and negatively associated with HDL cholesterol ($\beta = -0.062$, $P = 0.01$).

When we performed a multivariable analysis in which PEP and RSA were entered together, the odds ratios (ORs) and β s remained largely similar to the separate univariable analyses [e.g. for the metabolic syndrome, RSA OR = 0.83




FIG. 1. Mean adjusted RSA, heart rate, PEP, and CAB for the number of metabolic syndrome components. These were corrected for age, gender, education, alcohol use, smoking, physical activity, use of β -blocking agents, other cardiac medication, cardiovascular disease, menopause, and use of oral contraceptives.

(0.75–0.92) and PEP OR = 0.88 (0.82–0.95), P 's < 0.001], suggesting that both branches are independently associated with the metabolic syndrome and its components. To further investigate whether associations for sympathetic (PEP) and parasympathetic activity (RSA) with metabolic syndrome components were independent from each other, additional analysis were performed with the CAB and CoAR (Table 3). Results showed that the CAB, reflecting reciprocal SNS activation and PNS inhibition, significantly decreased the odds of metabolic syndrome [per 1 U increase in CAB OR = 0.75 (0.67–0.84)]. Moreover,

TABLE 4. Adjusted associations between the stress systems and the individual components of the metabolic syndrome^a

	Waist circumference		Triglycerides (log transformed)		HDL cholesterol		SBP		Glucose (log transformed)	
	β	<i>P</i>	β	<i>P</i>	β	<i>P</i>	β	<i>P</i>	β	<i>P</i>
ANS										
RSA (msec)	−0.078	0.005	−0.092	0.002	0.003	0.93	−0.111	<0.001	−0.066	0.02
HR (beats/min)	0.111	<0.001	0.186	<0.001	−0.062	0.01	0.151	<0.001	0.140	<0.001
PEP (msec)	−0.143	<0.001	−0.081	0.001	0.031	0.20	−0.115	<0.001	−0.031	0.20
CAB	−0.155	<0.001	−0.113	<0.001	0.023	0.36	−0.150	<0.001	−0.056	0.02
CoAR	0.083	0.01	0.019	0.49	−0.030	0.26	0.038	0.12	−0.011	0.69
HPA axis										
AUCg (nmol/liter)	−0.028	0.21	0.024	0.31	0.021	0.36	0.000	0.99	−0.015	0.52
AUCi (nmol/liter)	−0.039	0.07	0.013	0.57	−0.015	0.50	−0.014	0.50	−0.016	0.47
Evening cortisol (nmol/liter)	−0.023	0.25	0.029	0.18	0.002	0.92	0.035	0.08	−0.014	0.53
Suppression ratio	0.023	0.25	0.003	0.91	−0.005	0.83	−0.014	0.49	0.005	0.81

β , Standardized β -coefficient; HR, heart rate.

^a Based on linear regression analyses adjusted for age, sex, education, oral contraceptive use, menopause, cardiovascular disease, physical activity, smoking, alcohol use, and use of β -blockers and other heart medication. For HPA axis, analyses are additionally adjusted for working, awakening time, season, and sleep.

higher CAB was negatively associated with the number of metabolic dysregulations and all individual components of the metabolic syndrome (except for HDL cholesterol). The CoAR, reflecting SNS and PNS coactivation, did not associate with any of the metabolic measures.

Discussion

In this large study, we found that decreased PNS and increased SNS activity were associated with metabolic syndrome and its components, whereas HPA axis measures were not. The activity of the ANS and HPA stress systems was not correlated. These results suggest that in contrast to HPA axis dysregulation, ANS dysregulation is strongly associated with metabolic syndrome and might therefore partly be involved in its unfavorable consequences such as the incidence of cardiovascular disease.

The association of low PNS activity with the metabolic syndrome corroborates the findings of some groups (13, 15) and contrasts with other groups reporting no association. Previous studies had also reported on the associations between measures of SNS activity and metabolic syndrome, but the evidence was scarce and results were inconsistent (10, 12). The present study provides consistent evidence for an association of increased SNS activity (*i.e.* lower PEP) with the metabolic syndrome and individual metabolic components.

Although the effects of PEP and RSA on metabolic syndrome and its components were partly independent, a pat-

tern of parallel high SNS and low PNS activity was most strongly associated with metabolic syndrome. In contrast, a pattern of low SNS activity and low PNS activity or high SNS activity with high PNS activity did not show association with the metabolic syndrome. Our findings are strikingly congruent to results of Berntson *et al.* (32), who reported a similar relationship between ANS and diabetes. Taken together, these results suggest that especially the combination of increased SNS activity and decreased PNS activity is related to the metabolic syndrome, whereas high SNS activity in the presence of high PNS activity or low PNS activity in the presence of low SNS activity are not.

In line with several studies (10, 18), we found no relationship between salivary HPA axis measures and the metabolic syndrome or its components. These results suggest that the HPA axis is not dysregulated in persons with metabolic syndrome. Most studies that did find associations between salivary cortisol measures and several metabolic syndrome components were not comparable with our study because they studied solely men, used small samples, included only obesity measures, or used just one or two morning samples (22, 23). Important work has been done by Rosmond *et al.* (39), who reported that in men, a reduced variation in the diurnal cortisol pattern was associated with metabolic dysregulations and predicted higher risk of cardiovascular events after 5 yr. However, it is unclear how this abnormal cortisol pattern relates to our salivary cortisol measures. Other studies have found metabolic syndrome to be more frequently accompanied by

increased urinary cortisol rather than plasma or saliva cortisol (*e.g.* Ref. 10), which could be a result of increased cortisol excretion in combination with increased metabolism. Alternatively, HPA axis hyperresponsiveness after corticotrophin releasing hormone stimulation (40) or acute stress might be more strongly related to metabolic abnormalities, whereas basal activity remains intact.

It is a general belief that the autonomic nervous system and the HPA axis stress systems are highly intertwined (41) because both systems are centrally activated in response to stress, *e.g.* by the hypothalamus. In addition, both stress systems arouse each other: CRH, which drives HPA axis activity, also seems to stimulate sympathetic flow (42), and central catecholamines, an ANS marker, seem to stimulate the HPA axis (43). Although many hypotheses linking the two systems have emerged, previous studies directly correlating ANS and HPA axis measures under resting conditions are scarce. Our results suggest that both systems do not correlate very strongly, and only ANS activity is associated with an unfavorable metabolic state. Both stress systems are responsive and dynamic systems with different temporal courses. Previous studies showed that ANS activity remained high after repeated stress, whereas the HPA axis was desensitized and did not respond with hyperactivity (9), which might explain why the ANS and HPA axis did not correlate in our study. In addition, results of a study on the metabolic syndrome in relation to HPA axis and ANS measures in a sample of 180 men (10) are in accordance with ours; they reported strong associations between ANS measures and the metabolic syndrome, whereas HPA axis measures were not associated. Finally, it is possible that correlations between the ANS and the HPA axis become more apparent in response to acute stress but are lower when subjects are not experiencing acute stress, such as in our study.

Our study had several strengths, including a large sample size and multiple measures of the HPA axis and sympathetic as well as parasympathetic activity. In addition, it was presented that a specific pattern of parallel decrease in parasympathetic and increase in sympathetic activity was most strongly associated with metabolic dysregulations and the metabolic syndrome. Furthermore, all components that constitute the metabolic syndrome were separately analyzed, and the intercorrelation of both stress systems was investigated. Finally, our sample size enabled us to take important covariates into account. However, some limitations have to be acknowledged as well. First, because analyses were cross-sectional, our results do not indicate any causal direction of the associations found. Future longitudinal studies are warranted to further examine the relationship between the HPA axis, the ANS and metabolic dysregulations. Second, noncompliance with

cortisol sampling could have occurred because it was logistically and financially not feasible to electronically monitor compliance.

To conclude, although the ANS was strongly associated with metabolic syndrome and its individual components, the HPA axis was not. In particular, a parallel decrease in parasympathetic and increase in sympathetic activity were associated with metabolic dysregulations and could therefore have an important role in its higher risk of cardiovascular disease.

Acknowledgments

Address all correspondence and requests for reprints to: Carmilla M. M. Licht, M.Sc., Department of Psychiatry/EMGO⁺ Institute, Vrije Universiteit Medical Center, AJ Ernststraat 887, 1081 HL Amsterdam, The Netherlands. E-mail: c.licht@vumc.nl.

The infrastructure for the Netherlands Study of Depression and Anxiety (www.nesda.nl) is funded through the Geestkracht program of The Netherlands Organisation for Health Research and Development (Zon-Mw, Grant 10-000-1002) and is supported by participating universities and mental health care organizations (Vrije Universiteit Medical Center, Mental Health Care (GGZ) in-Geest, Arkin, Leiden University Medical Center, GGZ Rivierduinen, University Medical Center Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Scientific Institute for Quality of Healthcare, Netherlands Institute for Health Services Research, and Netherlands Institute of Mental Health and Addiction (Trimbos). Data analyses were supported by The Netherlands Organization of Scientific Research (NWO) Grant (Vidi, 917.66.320, to B.W.J.H.P.).

Disclosure Summary: The authors have nothing to disclose.

References

1. Chandola T, Brunner E, Marmot M 2006 Chronic stress at work and the metabolic syndrome: prospective study. *BMJ* 332:521–525
2. Hjemdahl P 2002 Stress and the metabolic syndrome: an interesting but enigmatic association. *Circulation* 106:2634–2636
3. Rosmond R 2005 Role of stress in the pathogenesis of the metabolic syndrome. *Psychoneuroendocrinology* 30:1–10
4. Anagnostis P, Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP 2009 Clinical review: the pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. *J Clin Endocrinol Metab* 94:2692–2701
5. Tentolouris N, Argyrakopoulou G, Katsilambros N 2008 Perturbed autonomic nervous system function in metabolic syndrome. *Neuromol Med* 10:169–178
6. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM 2007 Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. *J Am Coll Cardiol* 49:403–414
7. Guize L, Pannier B, Thomas F, Bean K, Jégo B, Benetos A 2008 Recent advances in metabolic syndrome and cardiovascular disease. *Arch Cardiovasc Dis* 101:577–583
8. Ford ES, Li C, Sattar N 2008 Metabolic syndrome and incident diabetes: current state of the evidence. *Diabetes Care* 31:1898–1904
9. Schommer NC, Hellhammer DH, Kirschbaum C 2003 Dissociation

- between reactivity of the hypothalamus-pituitary-adrenal axis and the sympathetic-adrenal-medullary system to repeated psychosocial stress. *Psychosom Med* 65:450–460
10. Brunner EJ, Hemingway H, Walker BR, Page M, Clarke P, Juneja M, Shipley MJ, Kumari M, Andrew R, Seckl JR, Papadopoulos A, Checkley S, Rumley A, Lowe GD, Stansfeld SA, Marmot MG 2002 Adrenocortical, autonomic, and inflammatory causes of the metabolic syndrome: nested case-control study. *Circulation* 106:2659–2665
 11. Huggett RJ, Burns J, Mackintosh AF, Mary DA 2004 Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. *Hypertension* 44:847–852
 12. Grassi G, Quarti-Trevano F, Seravalle G, Dell’Oro R, Dubini A, Mancia G 2009 Differential sympathetic activation in muscle and skin neural districts in the metabolic syndrome. *Metabolism* 58:1446–1451
 13. Koskinen T, Kähönen M, Jula A, Mattsson N, Laitinen T, Keltikangas-Järvinen L, Viikari J, Välimäki I, Rönnemaa T, Raitakari OT 2009 Metabolic syndrome and short-term heart rate variability in young adults. The cardiovascular risk in young Finns study. *Diabet Med* 26:354–361
 14. Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW, Cai J, Sharrett AR 1998 Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. *Diabetes Care* 21:2116–2122
 15. Min KB, Min JY, Paek D, Cho SI 2008 The impact of the components of metabolic syndrome on heart rate variability: using the NCEP-ATP III and IDF definitions. *Pacing Clin Electrophysiol* 31:584–591
 16. Gehi AK, Lampert R, Veledar E, Lee F, Goldberg J, Jones L, Murrain N, Ashraf A, Vaccarino V 2009 A twin study of metabolic syndrome and autonomic tone. *J Cardiovasc Electrophysiol* 20:422–428
 17. Kirschbaum C, Hellhammer DH 1994 Salivary cortisol in psychoneuroendocrine research: recent developments and applications. *Psychoneuroendocrinology* 19:313–333
 18. Kajantie E, Eriksson J, Osmond C, Wood PJ, Forsen T, Barker DJ, Phillips DI 2004 Size at birth, the metabolic syndrome and 24-h salivary cortisol profile. *Clin Endocrinol (Oxf)* 60:201–207
 19. Putignano P, Dubini A, Toja P, Invitti C, Bonfanti S, Redaelli G, Zappulli D, Cavagnini F 2001 Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol. *Eur J Endocrinol* 145:165–171
 20. Rosmond R, Björntorp P 2000 The hypothalamic-pituitary-adrenal axis activity as a predictor of cardiovascular disease, type 2 diabetes and stroke. *J Intern Med* 247:188–197
 21. Wirtz PH, von Känel R, Emini L, Ruedisueli K, Groessbauer S, Maercker A, Ehlert U 2007 Evidence for altered hypothalamus-pituitary-adrenal axis functioning in systemic hypertension: blunted cortisol response to awakening and lower negative feedback sensitivity. *Psychoneuroendocrinology* 32:430–436
 22. Phillips DI, Barker DJ, Fall CH, Seckl JR, Whorwood CB, Wood PJ, Walker BR 1998 Elevated plasma cortisol concentrations: a link between low birth weight and the insulin resistance syndrome? *J Clin Endocrinol Metab* 83:757–760
 23. Steptoe A, Kunz-Ebrecht SR, Brydon L, Wardle J 2004 Central adiposity and cortisol responses to waking in middle-aged men and women. *Int J Obes Relat Metab Disord* 28:1168–1173
 24. Penninx BW, Beekman AT, Smit JH, Zitman FG, Nolen WA, Spinhoven P, Cuijpers P, De Jong PJ, Van Marwijk HW, Assendelft WJ, Van Der Meer K, Verhaak P, Wensing M, De Graaf R, Hoogendijk WJ, Ormel J, Van Dyck R 2008 The Netherlands Study of Depression and Anxiety (NESDA): rationale, objectives and methods. *Int J Methods Psychiatr Res* 17:121–140
 25. Licht CM, de Geus EJ, Zitman FG, Hoogendijk WJ, van Dyck R, Penninx BW 2008 Association between major depressive disorder and heart rate variability in the Netherlands Study of Depression and Anxiety (NESDA). *Arch Gen Psychiatry* 65:1358–1367
 26. Vreeburg SA, Hoogendijk WJ, van Pelt J, DeRijk RH, Verhagen JC, van Dyck R, Smit JH, Zitman FG, Penninx BW 2009 Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. *Arch Gen Psychiatry* 66:617–626
 27. Vogelzangs N, Beekman AT, Kritchevsky SB, Newman AB, Pahor M, Yaffe K, Rubin SM, Harris TB, Satterfield S, Simonsick EM, Penninx BW 2007 Psychological risk factors and the metabolic syndrome in elderly persons: findings from the Health, Aging and Body Composition study. *J Gerontol A Biol Sci Med Sci* 62:563–569
 28. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F 2005 Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation* 112:2735–2752
 29. Licht CM, de Geus EJ, Seldenrijk A, van Hout HP, Zitman FG, van Dyck R, Penninx BW 2009 Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. *Hypertension* 53:631–638
 30. de Geus EJ, Willemsen GH, Klaver CH, van Doornen LJ 1995 Ambulatory measurement of respiratory sinus arrhythmia and respiration rate. *Biol Psychol* 41:205–227
 31. Willemsen GH, De Geus EJ, Klaver CH, Van Doornen LJ, Carroll D 1996 Ambulatory monitoring of the impedance cardiogram. *Psychophysiology* 33:184–193
 32. Berntson GG, Norman GJ, Hawkey LC, Cacioppo JT 2008 Cardiac autonomic balance versus cardiac regulatory capacity. *Psychophysiology* 45:643–652
 33. Vreeburg SA, Kruijtzter BP, van Pelt J, van Dyck R, DeRijk RH, Hoogendijk WJ, Smit JH, Zitman FG, Penninx BW 2009 Associations between sociodemographic, sampling and health factors and various salivary cortisol indicators in a large sample without psychopathology. *Psychoneuroendocrinology* 34:1109–1120
 34. van Aken MO, Romijn JA, Miltenburg JA, Lentjes EG 2003 Automated measurement of salivary cortisol. *Clin Chem* 49:1408–1409
 35. Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH 2003 Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. *Psychoneuroendocrinology* 28:916–931
 36. Edwards S, Clow A, Evans P, Hucklebridge F 2001 Exploration of the awakening cortisol response in relation to diurnal cortisol secretory activity. *Life Sci* 68:2093–2103
 37. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF, Oja P 2003 International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* 35:1381–1395
 38. Levine DW, Kripke DF, Kaplan RM, Lewis MA, Naughton MJ, Bowen DJ, Shumaker SA 2003 Reliability and validity of the Women’s Health Initiative Insomnia Rating Scale. *Psychol Assess* 15:137–148
 39. Rosmond R, Wallerius S, Wanger P, Martin L, Holm G, Björntorp P 2003 A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern. *J Intern Med* 254:386–390
 40. Pasquali R, Gagliardi L, Vicennati V, Gambineri A, Colitta D, Ceroni L, Casimirri F 1999 ACTH and cortisol response to combined corticotropin releasing hormone-arginine vasopressin stimulation in obese males and its relationship to body weight, fat distribution and parameters of the metabolic syndrome. *Int J Obes Relat Metab Disord* 23:419–424
 41. Axelrod J, Reisine TD 1984 Stress hormones: their interaction and regulation. *Science* 224:452–459
 42. Arlt J, Jahn H, Kellner M, Ströhle A, Yassouridis A, Wiedemann K 2003 Modulation of sympathetic activity by corticotropin-releasing hormone and atrial natriuretic peptide. *Neuropeptides* 37:362–368
 43. Plotsky PM, Cunningham Jr ET, Widmaier EP 1989 Catecholaminergic modulation of corticotropin-releasing factor and adrenocorticotropin secretion. *Endocr Rev* 10:437–458